Heron Therapeutics, Inc.

Heron Therapeutics, Inc.

HRTXNYSE / NASDAQHealthcareSmall cap

$0.25-$0.01 (-3.8%)

Last close · Data as of Nov 20, 2026

Market cap
$91.5M
Revenue
$154.9M
Net margin
-13.0%
ROCE
-6.9%

-76.4% over the last year

Heron Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-28.6%
3M
-19.4%
6M
-70.6%
1Y
-76.4%
5Y
-97.5%

52-week range

Day change -$0.01 (-3.8%) from $0.26 to $0.25 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in HRTX, bought on each weekday since 2021.

News & filings

What Heron Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 20.2 million US dollars in fiscal 2025.

Strengths (1)

  • EBITDA grew 63.7% in fiscal 2025, 56.3 points more than revenue.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Read moreShow less

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

Sector
Healthcare
Shares outstanding
188.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$91.5M
P/B
6.4x
EV / Sales
1.2x
P/S
0.6x
52-week high
$1.49
52-week low
$0.25

Profitability

Operating margin
-1.6%
Net margin
-13.0%
EBITDA margin
-5.3%
ROE
-141.0%
ROCE
-6.9%
ROIC
-6.6%
ROA
-7.9%
Asset turnover
0.61

Growth

Revenue
$154.9M
Revenue growth, 1Y
7.4%
Revenue CAGR, 3Y
12.9%
Net profit growth, 1Y
48.7%
Free cash flow
-$27.9M

Solvency

Current ratio
2.48
Debt / Equity
9.81
Debt / Assets
0.55
CFO / Net profit
1.37
Cash / Market cap
51.0%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$154.9M
Cost of revenue$41.4M
Gross profit$113.6M
Operating expenses$116.1M
Research and development$12.4M
Selling, general and administrative$103.7M
Operating income-$2.5M
Interest and other-$17.7M
Pretax income-$20.2M
Tax and other$0.00
Net income-$20.2M

Revenue and net profit

Revenue grew 7.4% in FY2025; net profit is the dashed line.

Heron Therapeutics, Inc. revenue and net profit by fiscal year
Heron Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$107.7M-$182.0M
FY2023$127.0M-$110.6M
FY2024$144.3M-$13.6M
FY2025$154.9M-$20.2M

Cash flows

FY2025: -$27.6M from operations, -$27.9M free after investment (dashed).

Heron Therapeutics, Inc. operating and free cash flow by fiscal year
Heron Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$146.9M-$148.7M
FY2023-$58.8M-$60.3M
FY2024-$22.5M-$24.2M
FY2025-$27.6M-$27.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$154.9M+7.4%1Y
EBITDA
-$8.3M
Net profit
-$20.2M
Cash from operations
-$27.6M
Free cash flow
-$27.9M
Revenue CAGR, 3Y
12.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$154.9M-$8.3M-$20.2M-$27.9M-152.0%+7.4%+48.7%

Monthly returns

Month-by-month returns of HRTX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$255.9M
Liabilities$241.5M
Equity$14.3M
Paid-in capital$2.0B
Retained earnings-$1.9B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; HRTX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Heron Therapeutics, Inc. (this company)1.2x

Not shown (no positive earnings and no EV / Sales): Aldeyra Therapeutics, Inc., Aardvark Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Heron Therapeutics, Inc.HRTXthis company$91.5M—6.4x-141.0%—
Aldeyra Therapeutics, Inc.ALDX$106.2M-3.1x2.4x-76.5%-1.6x
Cardiff Oncology, Inc.CRDF$106.0M-2.3x2.3x-101.0%-1.9x
Neuronetics, Inc.STIM$101.6M-2.6x4.5x-174.3%-5.8x
OptimizeRx CorporationOPRX$101.0M19.7x0.8x4.0%6.3x
Definitive Healthcare Corp.DH$95.7M-0.7x0.3x-49.4%-0.7x
Outset Medical, Inc.OM$87.7M-1.1x0.7x-64.3%-2.5x
Aardvark Therapeutics, Inc.AARD$86.0M-1.5x0.8x-54.0%-0.6x
biote Corp.BTMD$83.9M3.1x-1.4x-46.2%3.3x
Peer median—-1.3x0.8x-59.2%-1.2x

Year-to-date ROI

HRTX since 1 January, against earlier years.

Historical volatility

HRTX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Heron Therapeutics, Inc. operating margin by fiscal year
Heron Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-162.2%
FY2023-87.1%
FY2024-8.0%
FY2025-1.6%
LineFY2025
Cost of revenueCost Of Revenue$41.4M
Gross profitGross Profit$113.6M
Operating expensesOperating Expense$116.1M
Research and developmentResearch And Development$12.4M
Total expensesTotal Expenses$157.4M
Pretax incomePretax Income-$20.2M

Learn while you research

Academy chapters picked for Heron Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 9.81 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →